Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c

Reports cash, cash equivalents and short-term investments as of March 31 totaled $8.4M as compared to $8.5M as of December 31, 2025. The company said, “As previously communicated, Pierre Fabre Pharmaceuticals (PFP), with Atara’s support, had a productive meeting with the FDA and discussed a potential path forward to resubmitting the tab-cel Biologics License Application (BLA). The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a marketing application of tab-cel for the proposed indication. PFP has indicated they intend to submit an updated dataset with additional patients and longer follow-up from the pivotal Phase 3 single arm ALLELE study as well as supportive data, as a part of the resubmission plan being defined with the FDA. Atara anticipates providing a further regulatory update in the third quarter.”Atara said its operating expenses are “expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025.”